Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arbutus Biopharma Cp (NQ: ABUS )

2.030 -0.020 (-0.98%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arbutus Biopharma Cp

< Previous 1 2 3 Next >
Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Biotech firm Promosome has agreed to end the lawsuit, which accused the COVID-19 vaccine manufacturers, Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX), of patent infrin 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance
Via Benzinga
Recap: Arbutus Biopharma Q1 Earnings
Via Benzinga
Arbutus Biopharma's Earnings Outlook
Via Benzinga
Why Arbutus Biopharma Stock Is Sinking Today
After a strong start to 2023, the virology-focused biopharma company has hit a regulatory speed bump. 
Via The Motley Fool
Why Arbutus Biopharma Stock Is Plunging Today
Via Benzinga
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
Via Benzinga
Arbutus Biopharma's Return On Capital Employed Insights
Via Benzinga
Recap: Arbutus Biopharma Q2 Earnings
  Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Arbutus Biopharma: Q1 Earnings Insights
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Via Benzinga
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Investors can start off the day with a breakdown of the biggest pre-market stock movers for Tuesday and the news moving those shares! 
Via InvestorPlace
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
Moderna Inc (NASDAQ: MRNA) has  
Via Benzinga
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Monday, May 9
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive 
Via Benzinga
Moderna Files Motion To Dismiss COVID-19 Vaccine Related Patent Claims: WSJ
Moderna Inc (NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 vaccine, arguing that the companies may only pursue their claims by seeking... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Arbutus Biopharma Earnings Conference Call Is Coming Up, Here's What You Need To Know
Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents,  
Via Benzinga
Arbutus Biopharma Earnings Perspective: Return On Capital Employed
Benzinga Pro data, Arbutus Biopharma (NASDAQ:ABUS) reported Q4 sales of $3.21 million. Earnings fell to a loss of $21.32 million, resulting in a 11.29% decrease from last quarter... 
Via Benzinga
Arbutus Biopharma: Q4 Earnings Insights
Arbutus Biopharma (NASDAQ:ABUS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.... 
Via Benzinga
Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s)
Arbutus Biopharma Corporation (NASDAQ: ABUS) and Genevant have sued Moderna Inc (NASDAQ: MRNA) for infringing on their patent on a lipid... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
Earnings Scheduled For March 3, 2022
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
Futures, Global Markets Soar In Biggest 4-Day Rally Since November 2020
US equity futures and global stocks from Europe to Asia were headed for the biggest four-day rally since November 2020, supercharged by blockbuster earnings AMD and Google, which hit an all time high... 
Via Talk Markets
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.